Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)

Anika Therapeutics (ANIK) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 659000.0 as the latest value for Q4 2024.

  • Quarterly Liabilities from Discontinued Operations fell 93.9% to 659000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 659000.0 through Dec 2024, down 93.9% year-over-year, with the annual reading at 659000.0 for FY2024, 93.9% down from the prior year.
  • Liabilities from Discontinued Operations for Q4 2024 was 659000.0 at Anika Therapeutics, down from 10799000.0 in the prior quarter.
  • The five-year high for Liabilities from Discontinued Operations was 10799000.0 in Q4 2023, with the low at 659000.0 in Q4 2024.